Clinical trial · Observational
Exceptional Responders With Solid Tumor Cancer to Chemotherapy
Evaluation of Exceptional Responders With Solid Tumor Cancer
NCT02555735CI-TRIAL-00063577enrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study enrolling patients with Solid Tumor cancers to identify genomic expression differences between exceptional responders and non-responders to standard of care chemotherapy. Data analysis of the gene expression profile of the exceptional responders compared to non-responders will define genomic patterns that may help understand their response to chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor Neoplasms | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Standard of Care Chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Solid Tumor Cancer
- description
- Participants with solid tumor cancer treated with physician-choice standard of care chemotherapy.
- interventionNames
- Drug: Standard of Care Chemotherapy
Primary outcomes (1)
- measure
- Identify exceptional responders with cancer to standard of care chemotherapy
- timeFrame
- 9 years
- description
- Identify responders and non-responders
Secondary outcomes (1)
- measure
- Correlation of genomic profiles from circulating cells with overall survival
- timeFrame
- 9 years
- description
- Genomic expression profiles correlated with progression free and overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological confirmation of solid tumor carcinoma. * Patient is treatment-naïve or currently receiving chemotherapy. * ECOG performance status (any). Exclusion Criteria: * HIV positive on antiretroviral therapy * Pregnant or lactating * Prior organ allograft * Any medical or psychiatric condition that may interfere with the ability to comply with protocol treatment
References
Publications (3)
- BACKGROUNDYu KH, Ricigliano M, McCarthy B, Chou JF, Capanu M, Cooper B, Bartlett A, Covington C, Lowery MA, O'Reilly EM. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. Cancers (Basel). 2018 Nov 24;10(12):467. doi: 10.3390/cancers10120467. PMID 30477242
- BACKGROUNDIsacoff WH, Cooper B, Bartlett A, McCarthy B, Yu KH. ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer. Cancers (Basel). 2022 Jun 13;14(12):2906. doi: 10.3390/cancers14122906. PMID 35740571
- BACKGROUNDYu KH, Park J, Mittal A, Abou-Alfa GK, El Dika I, Epstein AS, Ilson DH, Kelsen DP, Ku GY, Li J, Park W, Varghese AM, Chou JF, Capanu M, Cooper B, Bartlett A, McCarthy D, Sangar V, McCarthy B, O'Reilly EM. Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Cancer. 2022 Aug 1;128(15):2958-2966. doi: 10.1002/cncr.34269. Epub 2022 Jun 1. PMID 35647938